News stories about Gilead Sciences (NASDAQ:GILD) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.6717814055713 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Gilead Sciences, Inc. (GILD) Upgraded to Buy by BidaskClub (americanbankingnews.com)
- Maxim Group Reaffirms “Hold” Rating for Gilead Sciences, Inc. (GILD) (wobko.net)
- Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada (finance.yahoo.com)
- Mylan Finalizes Settlement Agreement with DOJ for $465M (finance.yahoo.com)
- Gilead (GILD) Receives Approval in Canada for VOSEVI for Re-treatment of Certain Patients with Chronic HCV Infection (streetinsider.com)
Several equities research analysts have recently issued reports on GILD shares. Gabelli restated a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Stifel Nicolaus restated a “buy” rating and issued a $87.00 price objective on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a research note on Tuesday, May 2nd. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price objective on the stock. in a research note on Tuesday, April 25th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, April 21st. Eleven investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average price target of $80.31.
Gilead Sciences (NASDAQ:GILD) traded down 0.32% during trading on Friday, hitting $72.11. The stock had a trading volume of 6,052,601 shares. The company has a 50-day moving average of $72.61 and a 200 day moving average of $68.83. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $82.10. The company has a market cap of $94.17 billion, a price-to-earnings ratio of 7.83 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.08 earnings per share. On average, equities research analysts anticipate that Gilead Sciences will post $8.75 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.88%. Gilead Sciences’s payout ratio is 22.58%.
In other news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total value of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. In the last three months, insiders sold 206,666 shares of company stock valued at $15,223,184. Insiders own 1.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/19/gilead-sciences-gild-earns-media-impact-score-of-0-08-updated-updated-updated.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.